Patent Board Turns Away Challenge To Cancer Drug In Final Decision
ALEXANDRIA, Va. — A consolidated challenge to 22 claims of the patented cancer drug Alimta was rejected Oct. 5 by the Patent Trial and Appeal Board, which found that various petitions...To view the full article, register now.
Already a subscriber? Click here to view full article